We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > cardiovascular

News List

Phase III COMPASS study with Bayer's rivaroxaban (Xarelto®) shows overwhelming efficacy and meets pr worldpharmanews
February 15, 2017
Bayer AG and its cooperation partner Janssen Research & Development, LLC have announced that the Phase III trial COMPASS evaluating the efficacy and safety of rivaroxaban (Xarelto®) for the prevention of major adverse cardiac events (MACE)...
Amgen's Repatha significantly reduced the risk of cardiovascular events in FOURIER outcomes study cphi-online
February 08, 2017
Landmark Repatha cardiovascular outcomes study meets primary and key secondary endpoint.
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underly worldpharmanews
January 09, 2017
Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments...
FDA to review 3 new diabetes drugs that reduce cardiovascular death risk europeanpharmaceuticalreview
January 06, 2017
The US Food and Drug Administration (FDA) approved supplemental new drug applications for three type 2 diabetes medicines within the empagliflozin family to include data from the empa-red outcome trial.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page